Skip to main content
Gerald Falchook, MD, Oncology, Denver, CO

GeraldStevenFalchookMD

Oncology Denver, CO

Oncologist at Sarah Cannon Research

Dr. Falchook is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Falchook's full profile

Already have an account?

  • Office

    1800 Williams St
    300
    Denver, CO 80218
    Phone+1 720-754-2610
    Fax+1 720-754-2659

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 2001 - 2004
  • Louisiana State University School of Medicine in New Orleans
    Louisiana State University School of Medicine in New OrleansClass of 2001

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2004 - 2025
  • TX State Medical License
    TX State Medical License 2004 - 2015
  • PA State Medical License
    PA State Medical License 2004 - 2004
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors  
    David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine

Lectures

  • Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

Authored Content

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

  • Plain Language Summary of the Development of Tepotinib: A Treatment for a Subtype of Non-Small Cell Lung Cancer Called MET Exon 14 Skipping
    Plain Language Summary of the Development of Tepotinib: A Treatment for a Subtype of Non-Small Cell Lung Cancer Called MET Exon 14 SkippingMarch 31st, 2023
  • Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual Meeting
    Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
  • Sarah Cannon to Present Latest Cancer Research Insights at ASCO®20 Virtual Meeting
    Sarah Cannon to Present Latest Cancer Research Insights at ASCO®20 Virtual MeetingMay 28th, 2020
  • Join now to see all

Professional Memberships